{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:26:02Z","timestamp":1787142362269,"version":"build-2736575974"},"reference-count":5,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jaad.2026.05.071","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:41:39Z","timestamp":1779925299000},"page":"877-880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reducing immune checkpoint inhibitor discontinuation in dermatomyositis may improve survival: A systematic review"],"prefix":"10.1016","volume":"95","author":[{"given":"Mackenzie R.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Manduca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zasca-Aisha","family":"Ristianto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa N.","family":"Femia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2026.05.071_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2026.05.071_bib2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.55563\/clinexprheumatol\/brvl1v","article-title":"Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management","volume":"40","author":"Hallowell","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2026.05.071_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-11944-5","article-title":"Gene expression and molecular pathway analyses differentiate immunotherapy-induced myositis from spontaneous dermatomyositis","volume":"15","author":"R\u00f6ckel","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaad.2026.05.071_bib4","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.3390\/cancers17132063","article-title":"Management of triple M syndrome: a narrative review of immune checkpoint inhibitor-induced myasthenia gravis, myositis and myocarditis","volume":"17","author":"Furlepa","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaad.2026.05.071_bib5","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.3390\/ijms21093054","article-title":"Immune checkpoint inhibitor-related myositis: from biology to bedside","volume":"21","author":"Solimando","year":"2020","journal-title":"Int J Mol Sci"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226027647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226027647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:39:36Z","timestamp":1787139576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226027647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0190962226027647"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.05.071","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reducing immune checkpoint inhibitor discontinuation in dermatomyositis may improve survival: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.05.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}